S&P 500   5,061.82
DOW   37,735.11
QQQ   431.06
5 Small-Cap Energy Stocks Surged in Price and Volume on Friday
Novo Nordisk Arms Wegovy to Be a Triple Threat
Vital Farms Rides the Pasture-Raised Egg Trend to the Bank
3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
M&T Bank, Goldman Sachs rise; Salesforce, Tesla fall, Monday, 4/15/2024
When Will the Next Bull Market Be?
Global smartphone shipments climb nearly 8% in 1st quarter as Samsung retakes the lead
S&P 500   5,061.82
DOW   37,735.11
QQQ   431.06
5 Small-Cap Energy Stocks Surged in Price and Volume on Friday
Novo Nordisk Arms Wegovy to Be a Triple Threat
Vital Farms Rides the Pasture-Raised Egg Trend to the Bank
3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
M&T Bank, Goldman Sachs rise; Salesforce, Tesla fall, Monday, 4/15/2024
When Will the Next Bull Market Be?
Global smartphone shipments climb nearly 8% in 1st quarter as Samsung retakes the lead
S&P 500   5,061.82
DOW   37,735.11
QQQ   431.06
5 Small-Cap Energy Stocks Surged in Price and Volume on Friday
Novo Nordisk Arms Wegovy to Be a Triple Threat
Vital Farms Rides the Pasture-Raised Egg Trend to the Bank
3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
M&T Bank, Goldman Sachs rise; Salesforce, Tesla fall, Monday, 4/15/2024
When Will the Next Bull Market Be?
Global smartphone shipments climb nearly 8% in 1st quarter as Samsung retakes the lead
S&P 500   5,061.82
DOW   37,735.11
QQQ   431.06
5 Small-Cap Energy Stocks Surged in Price and Volume on Friday
Novo Nordisk Arms Wegovy to Be a Triple Threat
Vital Farms Rides the Pasture-Raised Egg Trend to the Bank
3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
M&T Bank, Goldman Sachs rise; Salesforce, Tesla fall, Monday, 4/15/2024
When Will the Next Bull Market Be?
Global smartphone shipments climb nearly 8% in 1st quarter as Samsung retakes the lead

MoonLake Immunotherapeutics (MLTX) Competitors

$43.64
-0.27 (-0.61%)
(As of 04/15/2024 ET)

MLTX vs. ACAD, INDV, HCM, IDYA, EVO, SMMT, MOR, XENE, ARWR, and CRNX

Should you be buying MoonLake Immunotherapeutics stock or one of its competitors? The main competitors of MoonLake Immunotherapeutics include ACADIA Pharmaceuticals (ACAD), Indivior (INDV), HUTCHMED (HCM), IDEAYA Biosciences (IDYA), Evotec (EVO), Summit Therapeutics (SMMT), MorphoSys (MOR), Xenon Pharmaceuticals (XENE), Arrowhead Pharmaceuticals (ARWR), and Crinetics Pharmaceuticals (CRNX). These companies are all part of the "pharmaceutical preparations" industry.

MoonLake Immunotherapeutics vs.

ACADIA Pharmaceuticals (NASDAQ:ACAD) and MoonLake Immunotherapeutics (NASDAQ:MLTX) are both mid-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, earnings, risk, community ranking, dividends, media sentiment, institutional ownership, analyst recommendations and profitability.

In the previous week, ACADIA Pharmaceuticals had 26 more articles in the media than MoonLake Immunotherapeutics. MarketBeat recorded 37 mentions for ACADIA Pharmaceuticals and 11 mentions for MoonLake Immunotherapeutics. ACADIA Pharmaceuticals' average media sentiment score of 0.31 beat MoonLake Immunotherapeutics' score of -0.05 indicating that MoonLake Immunotherapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
ACADIA Pharmaceuticals
7 Very Positive mention(s)
2 Positive mention(s)
9 Neutral mention(s)
5 Negative mention(s)
0 Very Negative mention(s)
Neutral
MoonLake Immunotherapeutics
1 Very Positive mention(s)
2 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

MoonLake Immunotherapeutics has a net margin of 0.00% compared to MoonLake Immunotherapeutics' net margin of -8.44%. ACADIA Pharmaceuticals' return on equity of -9.22% beat MoonLake Immunotherapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
ACADIA Pharmaceuticals-8.44% -15.67% -9.15%
MoonLake Immunotherapeutics N/A -9.22%-9.00%

96.7% of ACADIA Pharmaceuticals shares are owned by institutional investors. Comparatively, 93.9% of MoonLake Immunotherapeutics shares are owned by institutional investors. 27.5% of ACADIA Pharmaceuticals shares are owned by insiders. Comparatively, 15.3% of MoonLake Immunotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

ACADIA Pharmaceuticals received 827 more outperform votes than MoonLake Immunotherapeutics when rated by MarketBeat users. However, 75.86% of users gave MoonLake Immunotherapeutics an outperform vote while only 73.07% of users gave ACADIA Pharmaceuticals an outperform vote.

CompanyUnderperformOutperform
ACADIA PharmaceuticalsOutperform Votes
871
73.07%
Underperform Votes
321
26.93%
MoonLake ImmunotherapeuticsOutperform Votes
44
75.86%
Underperform Votes
14
24.14%

ACADIA Pharmaceuticals has a beta of 0.37, meaning that its stock price is 63% less volatile than the S&P 500. Comparatively, MoonLake Immunotherapeutics has a beta of 1.2, meaning that its stock price is 20% more volatile than the S&P 500.

ACADIA Pharmaceuticals currently has a consensus target price of $35.82, indicating a potential upside of 112.10%. MoonLake Immunotherapeutics has a consensus target price of $74.46, indicating a potential upside of 70.63%. Given MoonLake Immunotherapeutics' stronger consensus rating and higher probable upside, analysts clearly believe ACADIA Pharmaceuticals is more favorable than MoonLake Immunotherapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ACADIA Pharmaceuticals
0 Sell rating(s)
3 Hold rating(s)
12 Buy rating(s)
0 Strong Buy rating(s)
2.80
MoonLake Immunotherapeutics
0 Sell rating(s)
3 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.75

MoonLake Immunotherapeutics has lower revenue, but higher earnings than ACADIA Pharmaceuticals. MoonLake Immunotherapeutics is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ACADIA Pharmaceuticals$726.44M3.83-$61.29M-$0.38-44.45
MoonLake ImmunotherapeuticsN/AN/A-$36.01M-$0.76-57.42

Summary

ACADIA Pharmaceuticals beats MoonLake Immunotherapeutics on 10 of the 17 factors compared between the two stocks.

Get MoonLake Immunotherapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for MLTX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MLTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MLTX vs. The Competition

MetricMoonLake ImmunotherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$2.79B$6.66B$4.83B$7.49B
Dividend YieldN/A3.07%5.53%3.96%
P/E Ratio-57.4216.64248.9219.11
Price / SalesN/A335.352,495.3991.23
Price / CashN/A20.1333.2728.20
Price / Book5.355.614.674.26
Net Income-$36.01M$132.79M$100.02M$210.92M
7 Day Performance-6.65%-5.11%-4.44%-4.38%
1 Month Performance-7.64%-4.45%-2.92%-2.08%
1 Year Performance129.20%3.09%12.64%6.73%

MoonLake Immunotherapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ACAD
ACADIA Pharmaceuticals
3.6605 of 5 stars
$18.15
+2.0%
$36.12
+99.0%
-6.1%$2.99B$726.44M-47.76597Short Interest ↑
INDV
Indivior
3.2405 of 5 stars
$21.10
-0.9%
$36.00
+70.6%
N/A$2.91B$1.09B-1,054.471,164News Coverage
Positive News
Gap Up
HCM
HUTCHMED
1.5158 of 5 stars
$17.94
+6.3%
$29.70
+65.6%
-0.4%$3.13B$838M0.001,988Gap Up
High Trading Volume
IDYA
IDEAYA Biosciences
2.5072 of 5 stars
$42.57
+1.4%
$44.55
+4.6%
+200.8%$3.17B$23.39M-21.61124Short Interest ↑
EVO
Evotec
1.5001 of 5 stars
$7.83
-0.5%
$14.00
+78.8%
N/A$2.77B$791.73M0.004,952Analyst Upgrade
Short Interest ↑
Gap Up
SMMT
Summit Therapeutics
1.7232 of 5 stars
$4.08
+3.3%
$8.00
+96.1%
+132.8%$2.77B$700,000.00-2.67105Short Interest ↑
MOR
MorphoSys
0.5785 of 5 stars
$18.16
+0.1%
$11.78
-35.1%
+246.5%$2.74B$257.89M-11.64524Short Interest ↓
XENE
Xenon Pharmaceuticals
1.5702 of 5 stars
$43.03
+1.0%
$58.67
+36.3%
+16.0%$3.25B$9.43M-15.82251Analyst Report
ARWR
Arrowhead Pharmaceuticals
4.0782 of 5 stars
$26.25
+2.1%
$53.45
+103.6%
-21.2%$3.25B$181.74M-9.44525
CRNX
Crinetics Pharmaceuticals
3.6527 of 5 stars
$46.91
+1.0%
$54.17
+15.5%
+174.2%$3.26B$4.01M-12.68290

Related Companies and Tools

This page (NASDAQ:MLTX) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners